Self-Reported Cognitive Function in Metabolic Dysfunction–associated Steatotic Liver Disease and Metabolic Dysfunction–associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom Trials
- 5 March 2026
- journal article
- Published by Elsevier in Journal of Clinical and Experimental Hepatology
- Vol. 16 (4) , 103531
Abstract
No abstract availableKeywords
Funding Information
- Madrigal Pharmaceuticals
This publication has 14 references indexed in Scilit:
- Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosisHepatology Communications, 2026
- Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosisHepatology, 2024
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver FibrosisNew England Journal of Medicine, 2024
- Cognitive impairment and liver fibrosis in non-alcoholic fatty liver diseaseBMJ Neurology Open, 2024
- Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trialNature Medicine, 2023
- Nonalcoholic fatty liver disease from a primary care perspectiveDiabetes, Obesity and Metabolism, 2023
- Is there an association between non-alcoholic fatty liver disease and cognitive function? A systematic reviewBMC Geriatrics, 2022
- B vitamins and prevention of cognitive decline and incident dementia: a systematic review and meta-analysisNutrition Reviews, 2021
- Development and Evaluation of The Liver Disease Quality of Life Instrument in Persons With Advanced, Chronic Liver Disease—The Ldqol 1.0American Journal of Gastroenterology, 2000
- Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver diseaseGut, 1999